SCHEMBL1466091

SCHEMBL1466091

NC(=O)N1C=CCc2cc3ccccc3cc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.37
GAA P10253 3/20 0.37
KDM4E B2RXH2 3/20 0.37
MYC P01106 1/20 0.36
CD74 P04233 1/20 0.36
MIF P14174 1/20 0.36
HRH4 Q9H3N8 1/20 0.35
IDO1 P14902 1/20 0.35
MAPT P10636 3/20 0.35
POLB P06746 1/20 0.35
MEN1 O00255 6/20 0.34
KMT2A Q03164 6/20 0.34
HPGD P15428 3/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
LMNA P02545 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
RAB9A P51151 2/20 0.33
IRAK4 Q9NWZ3 1/20 0.33
MITF O75030 1/20 0.33
NCOA1 Q15788 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15456828 0.85 MYC (0.41) ALDH1A1KDM4EMYCCD74MIF
SCHEMBL3266678 0.81 MEN1 (0.41) ALDH1A1KDM4ECD74MIFMAPT
SCHEMBL7035188 0.69 SMN1; SMN2 (0.37) ALDH1A1KDM4ECD74MIFMAPT
SCHEMBL1629578 0.66 NPC1 (0.39) ALDH1A1KDM4EMAPTPOLBMEN1
SCHEMBL308186 0.65 MEN1 (0.48) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL30003181 0.65 MEN1 (0.48) ALDH1A1KDM4EMAPTMEN1KMT2A
SCHEMBL3241412 0.63 SMN1; SMN2 (0.38) ALDH1A1KDM4EMAPTPOLBMEN1
Anthracene SCHEMBL28140459 0.63 ALDH1A1 (0.58) ALDH1A1GAAKDM4EIDO1MAPT
SCHEMBL1004596 0.62 KDM4E (0.63) ALDH1A1GAAKDM4EIDO1MAPT
SCHEMBL5968259 0.62 MEN1 (0.44) ALDH1A1GAAKDM4EMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110071165-A1 Aza- and polyazanthranyl amides and their use as medicaments NOVARTIS AG (CH) 2011-03-24 US disclosed
US-20110071165-A1 Aza- and polyazanthranyl amides and their use as medicaments NOVARTIS AG (CH) 2011-03-24 US disclosed
US-20110071165-A1 Aza- and polyazanthranyl amides and their use as medicaments NOVARTIS AG (CH) 2011-03-24 US disclosed
US-20080293696-A1 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents BAYER PHARMACEUTICALS CORPORATION (US) 2008-11-27 US disclosed
EP-1765811-A2 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS Bayer Pharmaceuticals Corporation (US) 2007-03-28 EP disclosed
US-20060287339-A1 Aza- and polyazanthranyl amides and their use as medicaments SEIDELMANN DIETER 2006-12-21 US disclosed
US-20060287339-A1 Aza- and polyazanthranyl amides and their use as medicaments SEIDELMANN DIETER 2006-12-21 US disclosed
US-20060287339-A1 Aza- and polyazanthranyl amides and their use as medicaments SEIDELMANN DIETER 2006-12-21 US disclosed
WO-2006002383-A2 2-AMINOARYLCARBOXAMIDES USEFUL AS CANCER CHEMOTHERAPEUTIC AGENTS BAYER PHARMACEUTICALS CORPORATION (US) 2006-01-05 WO disclosed
US-20040224968-A1 Aza-and polyazanthranyl amides and their use as medicaments NOVARTIS AG (CH) 2004-11-11 US disclosed
US-20040224968-A1 Aza-and polyazanthranyl amides and their use as medicaments NOVARTIS AG (CH) 2004-11-11 US disclosed
US-20040224968-A1 Aza-and polyazanthranyl amides and their use as medicaments NOVARTIS AG (CH) 2004-11-11 US disclosed
WO-2001085715-A3 AZA- AND POLYAZANTHRANYL AMIDES AND THEIR USE AS MEDICAMENTS NOVARTIS AG (CH) 2002-04-18 WO disclosed
WO-2001085715-A2 AZA- AND POLYAZANTHRANYL AMIDES AND THEIR USE AS MEDICAMENTS NOVARTIS AG (CH) 2001-11-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287339-A1 Aza- and polyazanthranyl amides and their use as medicaments VEGFA, AZI2, TPMT ALDH1A1 764/4885GAA 371/4885KDM4E 745/4885
US-20040224968-A1 Aza-and polyazanthranyl amides and their use as medicaments AZI2, VEGFA, TPMT ALDH1A1 530/4885GAA 849/4885KDM4E 415/4885
US-20080293696-A1 2-Aminoarylcarboxamides Useful as Cancer Chemotherapeutic Agents ABCC3, HCCS, ABCC2 ALDH1A1 611/4885GAA 4062/4885KDM4E 975/4885
US-20110071165-A1 Aza- and polyazanthranyl amides and their use as medicaments VEGFA, AZI2, TPMT ALDH1A1 764/4885GAA 371/4885KDM4E 745/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.